Orally bioavailable small molecule drug protects memory in Alzheimer's disease models

Eugene O'Hare, D.I.C. Scopes, E-M. Kim, Philip Palmer, M. Jones, A.D. Whyment, D. Spanswick, H. Amijee, E. Nerou, Bridgeen McMahon, J.M. Treherne, R. Jeggo

Research output: Contribution to journalArticlepeer-review

14 Citations (Scopus)
264 Downloads (Pure)


Oligomers of beta-amyloid (Aß) are implicated in the early memory impairment seen in Alzheimer's disease before to the onset of discernable neurodegeneration. Here, the capacity of a novel orally bioavailable, central nervous system-penetrating small molecule 5-aryloxypyrimidine, SEN1500, to prevent cell-derived (7PA2 [conditioned medium] CM) Aß-induced deficits in synaptic plasticity and learned behavior was assessed. Biochemically, SEN1500 bound to Aß monomer and oligomers, produced a reduction in thioflavin-T fluorescence, and protected a neuronal cell line and primary cortical neurons exposed to synthetic soluble oligomeric Aß1-42. Electrophysiologically, SEN1500 alleviated the in vitro depression of long-term potentiation induced by both synthetic Aß1-42 and 7PA2 CM, and alleviated the in vivo depression of long-term potentiation induced by 7PA2 CM, after systemic administration. Behaviorally, oral administration of SEN1500 significantly reduced memory-related deficits in operant responding induced after intracerebroventricular injection of 7PA2 CM. SEN1500 reduced cytotoxicity, acute synaptotoxicity, and behavioral deterioration after in vitro and in vivo exposure to synthetic Aß and 7PA2 CM, and shows promise for development as a clinically viable disease-modifying Alzheimer's disease treatment. © 2013 Elsevier Inc.

Original languageEnglish
Pages (from-to)1116-1125
JournalNeurobiology of Aging
Issue number4
Publication statusPublished - Apr 2013

Fingerprint Dive into the research topics of 'Orally bioavailable small molecule drug protects memory in Alzheimer's disease models'. Together they form a unique fingerprint.

Cite this